Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial

被引:32
|
作者
Kapp, Joshua R. [1 ]
Diss, Tim [2 ]
Spicer, James [3 ]
Gandy, Michael [2 ]
Schrijver, Iris [4 ]
Jennings, Lawrence J. [5 ]
Li, Marilyn M. [6 ]
Tsongalis, Gregory J. [7 ]
de Castro, David Gonzalez [8 ]
Bridge, Julia A. [9 ]
Wallace, Andrew [10 ]
Deignan, Joshua L. [11 ]
Hing, Sandra [12 ]
Butler, Rachel [13 ]
Verghese, Eldo [14 ]
Latham, Gary J. [15 ]
Hamoudi, Rifat A. [1 ]
机构
[1] UCL, Div Surg & Intervent Sci, London W1W 7EJ, England
[2] UCL, Univ Coll London Adv Diagnost, London W1W 7EJ, England
[3] Guys & St Thomas Hosp NHS Trust, Div Res Oncol, London, England
[4] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA
[5] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[7] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA
[8] Royal Marsden Hosp NHS Trust, Inst Canc Res, London, England
[9] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE USA
[10] Cent Manchester Univ Hosp NHS Trust, Reg Genet Lab, Manchester, Lancs, England
[11] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA
[12] Great Ormond St Hosp Sick Children, Paediat Malignancy Dept, London WC1N 3JH, England
[13] All Wales Genet Lab, Cardiff, S Glam, Wales
[14] Univ Leeds, Leeds, W Yorkshire, England
[15] Asuragen, Austin, TX USA
关键词
PCR; MOLECULAR PATHOLOGY; diagnostic screening; MELANOMA; LUNG CANCER; CELL LUNG-CANCER; EXTERNAL QUALITY ASSESSMENT; GEFITINIB; DNA; QUANTIFICATION; LYMPHOPROLIFERATIONS; STANDARDIZATION; CHEMOTHERAPY;
D O I
10.1136/jclinpath-2014-202644
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims Mutation detection accuracy has been described extensively; however, it is surprising that pre-PCR processing of formalin-fixed paraffin-embedded (FFPE) samples has not been systematically assessed in clinical context. We designed a RING trial to (i) investigate pre-PCR variability, (ii) correlate pre-PCR variation with EGFR/BRAF mutation testing accuracy and (iii) investigate causes for observed variation. Methods 13 molecular pathology laboratories were recruited. 104 blinded FFPE curls including engineered FFPE curls, cell-negative FFPE curls and control FFPE tissue samples were distributed to participants for pre-PCR processing and mutation detection. Follow-up analysis was performed to assess sample purity, DNA integrity and DNA quantitation. Results Rate of mutation detection failure was 11.9%. Of these failures, 80% were attributed to pre-PCR error. Significant differences in DNA yields across all samples were seen using analysis of variance (p<0.0001), and yield variation from engineered samples was not significant (p=0.3782). Two laboratories failed DNA extraction from samples that may be attributed to operator error. DNA extraction protocols themselves were not found to contribute significant variation. 10/13 labs reported yields averaging 235.8ng (95% CI 90.7 to 380.9) from cell-negative samples, which was attributed to issues with spectrophotometry. DNA measurements using Qubit Fluorometry demonstrated a median fivefold overestimation of DNA quantity by Nanodrop Spectrophotometry. DNA integrity and PCR inhibition were factors not found to contribute significant variation. Conclusions In this study, we provide evidence demonstrating that variation in pre-PCR steps is prevalent and may detrimentally affect the patient's ability to receive critical therapy. We provide recommendations for preanalytical workflow optimisation that may reduce errors in down-stream sequencing and for next-generation sequencing library generation.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 4 条
  • [1] EGFR and BRAF Mutation Detection in FFPE Samples of Lung Adenocarcinoma
    Yang Yang
    Zhang Hang
    Shen Xiaoyan
    Yu Lixia
    Liu Baorui
    Wang Lifeng
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1493 - S1494
  • [2] Anglo-American Ring Trial Unveils Pre-PCR Error and False-Negative Results in BRAF and EGFR Clinical Cancer Diagnostics
    Kapp, J. R.
    Hamoudi, R. A.
    Diss, T.
    Schrijver, I.
    Jennings, L. J.
    Li, M.
    Tsongalis, G. J.
    de Castro, D.
    Bridge, J.
    Butler, R.
    Wallace, A.
    Hing, S.
    Spicer, J.
    Verghese, E.
    Latham, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 927 - 927
  • [3] Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples
    Didelot, Audrey
    Le Corre, Delphine
    Luscan, Armelle
    Cazes, Aurelie
    Pallier, Karine
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    Blons, Helene
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2012, 92 (03) : 275 - 280
  • [4] Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
    Simarro, Javier
    Perez-Simo, Gema
    Mancheno, Nuria
    Ansotegui, Emilio
    Francisco Munoz-Nunez, Carlos
    Gomez-Codina, Jose
    Juan, Oscar
    Palanca, Sarai
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)